Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial.
Authors
Jänne, Pvan den Heuvel, M
Barlesi, F
Cobo, M
Mazieres, J
Crinò, L
Orlov, S
Blackhall, Fiona H
Wolf, J
Garrido, P
Poltoratskiy, A
Mariani, G
Ghiorghiu, D
Kilgour, E
Smith, P
Kohlmann, A
Carlile, D
Lawrence, D
Bowen, K
Vansteenkiste, J
Affiliation
Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MassachusettsIssue Date
2017
Metadata
Show full item recordAbstract
There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer.Citation
Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial. 2017, 317 (18):1844-1853 JAMAJournal
JAMADOI
10.1001/jama.2017.3438PubMed ID
28492898Type
ArticleLanguage
enISSN
1538-3598ae974a485f413a2113503eed53cd6c53
10.1001/jama.2017.3438
Scopus Count
Collections
Related articles
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
- Authors: Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L
- Issue date: 2013 Jan
- SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
- Authors: Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA
- Issue date: 2017 Dec 1
- Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
- Authors: Jänne PA, Mann H, Ghiorghiu D
- Issue date: 2016 Mar
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
- Authors: Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA
- Issue date: 2015 May
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
- Authors: Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S, LUME-Lung 1 Study Group
- Issue date: 2014 Feb